Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 51 - Preparations containing radioactive substances for use in therapy or testing in vivo
Patents for A61K 51 - Preparations containing radioactive substances for use in therapy or testing in vivo (24,291)
09/2005
09/14/2005EP1572724A2 Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
09/14/2005EP1572601A1 Solid-phase preparation of 18 f-labelled amino acids
09/14/2005EP1572249A1 Solid-phase fluorination of uracil and cytosine
09/14/2005EP1572248A2 Solid-phase fluorination of benzothiazoles
09/14/2005EP1572247A1 Radioablation of hemolymphopoietic cell populations
09/14/2005EP1572239A1 Method of using a cox-2 inhibitor and a topoisomerase ii inhibitor as a combination therapy in the treatment of neoplasia
09/14/2005EP1572131A2 Antibody therapy
09/14/2005EP1572074A2 Stabilized synthetic immunogen delivery system
09/14/2005EP1289414B1 Combined impedance imaging and mammography
09/14/2005EP1284958B1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using aminoidane derivatives
09/14/2005EP1092028B1 Specific binding proteins including antibodies which bind to the necrotic centre of tumours, and uses thereof
09/14/2005CN1668335A Drug pre-targeting by means of bi-specific antibodies and hapten constructs comprising a carrier peptide and the active agent(s)
09/13/2005US6943199 Eating disorders; psychological disorders; antidiabetic agents; cardiovascular disorders
09/13/2005US6942985 Diagnosisng colon or rectal cancer in mammals; obtain tissue sample, detect concentration of preferential receptor protein, amplified concentration of protein indicates cancer
09/09/2005WO2005083064A1 Cancerous disease modifying antibodies
09/09/2005WO2005083063A1 Cancerous disease modifying antibodies
09/09/2005WO2005082894A1 Cell targeting conjugates
09/09/2005WO2005082425A1 Catalytic radiofluorination
09/09/2005WO2005048810A3 Sigma-2 receptor radiotracers for imaging the proliferative status of solid tumors
09/09/2005WO2004096998A3 Nanoparticular tumor targeting and therapy
09/09/2005WO2004096144A3 Compositions and methods for induction of opioid receptors
09/09/2005CA2825161A1 Catalytic radiofluorination
09/09/2005CA2599304A1 Cell targeting conjugates
09/09/2005CA2557093A1 Cancerous disease modifying antibodies
09/09/2005CA2557091A1 Cancerous disease modifying antibodies
09/09/2005CA2552356A1 Catalytic radiofluorination
09/08/2005US20050196793 Using aberrant expression of caudal type homeobox transcription factor 2 (CDX2) as diagnostic indicator of stomach or esophageal cell proliferative disorers
09/08/2005US20050196339 For detecting and locating recurrence of cancer, radiation and drug resistance, and/or metastasis
09/07/2005EP1569690A1 Antilymphoma targeting agents with effector and affinity functions linked by a trifunctional reagent
09/07/2005CN1665933A Immunoconjugates for the treatment of tumours
09/07/2005CN1665815A Novel tetracyclo-aryl-carbonyl indoles used as therapeutical agents with 5-hydroxy-tryptamine receptor affinity, their preparation process and pharmaceutical compounds containing same
09/07/2005CN1663985A Biodegradable fluorescent polyphosphonitrile and process for synthesis therof
09/07/2005CN1663617A Biodegradable medical material marker and preparation thereof
09/07/2005CN1217924C Fluoro labelled aliphatic acid myocardial metabolic imaging agent 14 (R, S)-Fluoro[18F]-6-thio cydonic acid purifying method
09/06/2005US6939966 administering to a mammal a trans-N-[5-(2-fluorophenyl)-2-pyrimidinyl]-3-[11C]-oxospiro[5-azaisobenzofurane-1(3H), 1'-cyclohexane]-4'-carboxamide or a pharmaceutically acceptable salt for diagnostic imaging of tissues bearing neuropeptide YY5
09/06/2005US6939677 useful for detection, diagnosis, and treatment of breast cancer; Human milk fat globule ( HMFG)
09/01/2005WO2005080586A1 Fusion proteins containing recombinant cytotoxic rnases
09/01/2005WO2005079868A2 Crf receptor antagonists, their preparations, their pharmaceutical composition and their uses
09/01/2005WO2005079867A2 Alpha-emitting hydroxyapatite particles
09/01/2005WO2005079866A1 Technetium-and rhenium-bis(heteroaryl) complexes, and methods of use thereof
09/01/2005WO2005079865A1 Technetium- and rhenium-bis(heteroaryl) complexes, and methods of use thereof
09/01/2005WO2005079864A2 Improvement in the ligand protection for mercaptoacetyl triglycine
09/01/2005WO2005079863A1 Contrast medium for thrombus formation
09/01/2005WO2005079830A1 Inhibitors of amyloid fibril formation and uses thereof
09/01/2005WO2005079757A2 Therapeutic agent carrier compositions
09/01/2005WO2005079490A2 Methods of therapy and diagnosis using targeting of cells that express steap2 polypeptides
09/01/2005WO2005079391A2 Contrast agents for myocardial perfusion imaging
09/01/2005WO2005079155A2 Photoreactive compound specifically binding to calcium binding proteins
09/01/2005WO2005067388A3 Perturbed membrane-binding compounds and methods of using the same
09/01/2005US20050192458 Tumor imaging compounds
09/01/2005US20050191306 Cancerous disease modifying antibodies
09/01/2005US20050191305 Cancerous disease modifying antibodies
09/01/2005US20050191300 Immunotherapy of autoimmune disorders using antibodies which target B-cells
09/01/2005US20050191240 Peptide analogs of neurotensin resistant to enzymatic degradation and retain high binding affinity for neurotensin receptors; metal chelating group on one end; replacing Arg8 with Gly(PipAm) ((N-amidinopiperidinyl)glycine) for example; useful for diagnostic and therapeutic purposes
09/01/2005US20050191239 Reacting a 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid, DOTA chelating agent and a protein to form the conjugate, reacting the conjugate with a quenching agent of hydroxylamine at an alkaline pH
09/01/2005US20050191238 imaging myocardial perfusion, comprising administering to a patient a contrast agent which comprises a compound that binds MC-1, and an imaging moiety, and scanning the patient using diagnostic imaging.
09/01/2005DE19964224B4 Pharmazeutische Mittel enthaltend Calcium-Komplex von Pharmaceutical preparations containing calcium complex of [[(4R)-4-[bis[(carboxy-.kappa.O)methyl]amino-.kappa.N]-6,9-bis[(carboxy-.kappa.O)methyl]-1-[(4,4-diphenylcyclohexyl)oxy]-1-hydroxy-2-oxa-6,9-diaza-1-phosphaundecan-11-yl-säure-.kappa.N6,.kappa.N9,.kappa.011]1-oxidato(6-)]-, tetrahydrogen (MS-325) und dessen Salze sowie Verfahren zur Herstellung der Mittel tetra hydrogen (MS-325) and salts thereof as well as methods for preparing the compositions
09/01/2005DE102004008459A1 Implant, useful as stents, comprises a fabric and at least a radiopaque marker, which passes in a direction along the implant
09/01/2005DE102004005280A1 Verfahren und Kit zur Herstellung von Rhenium-188 markierten Partikeln A method and kit for the preparation of rhenium-188 labeled particles
09/01/2005CA2828128A1 Contrast agents for myocardial perfusion imaging
09/01/2005CA2558064A1 Contrast medium for thrombus formation
09/01/2005CA2556213A1 Contrast agents for myocardial perfusion imaging
09/01/2005CA2556054A1 Photoreactive compound specifically binding to calcium binding proteins
09/01/2005CA2555963A1 Technetium-and rhenium-bis(heteroaryl) complexes, and methods of use thereof
09/01/2005CA2555959A1 Technetium- and rhenium-bis(heteroaryl) complexes, and methods of use thereof
09/01/2005CA2555953A1 Improvement in the ligand protection for mercaptoacetyl triglycine
09/01/2005CA2555661A1 Fusion proteins containing recombinant cytotoxic rnases
08/2005
08/31/2005EP1567550A2 Peptide conjugate useful for cell nucleus molecular imaging and tumor therapy
08/31/2005EP1567495A2 Small technetium-99m and rhenium labeled agents and methods for imaging tissues, organs and tumors
08/31/2005EP1567141A1 Labeled macrophage scavenger receptor antagonists for imaging cardiovacular diseases
08/31/2005EP1392714B1 Steroids as agonists for fxr
08/31/2005EP1259264A4 Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation
08/31/2005CN1662263A Vitamin-targeted imaging agents
08/31/2005CN1660961A Method for preparing biological functional water-soluble quantum point of sugar
08/31/2005CN1660960A Method for preparing water-soluble quantum point of biological functionalized sugar
08/31/2005CN1216644C Tin-117m-containing radio therapeutic agents
08/31/2005CN1216604C Hexahydroindenopyridine compounds having antispermatogenic activity
08/30/2005US6936700 Radiolabeled chelation compounds used in pharmaceuticals for diagnostic and therapeutic purposes
08/30/2005US6936272 10139483Therapeutic liposome composition and method of preparation
08/30/2005US6936240 Method for the preparation of technetium or rhenium complex for radiopharmaceuticals
08/25/2005WO2005077967A1 Radiolabeled compounds and compositions, their precursors and methods for their production
08/25/2005WO2005077962A2 Crowned dithiocarbamate metal complexes and methods for their use
08/25/2005WO2005077343A2 Novel drugs and diagnostic compositions for use in the treatment and diagnosis of neurodegenerative diseases or amyloid diseases
08/25/2005WO2005077071A2 Therapeutic and diagnostic conjugates for use with multispecific antibodies
08/25/2005WO2005041656A3 Methods, compositions and devices for inducing stasis in tissues and organs
08/25/2005WO2005039291A3 Methods, compositions and devices for inducing stasis in cells
08/25/2005US20050186665 Expressed ligand - vascular intercellular signaling molecule
08/25/2005US20050186649 Inhibitors of human plasmin derived from the kunitz domains
08/25/2005US20050186574 Anterior gradient 2 homolog (AGR2) for use as to in identifying modulator for treatment of asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, vision defects, inflammatory bowel and cell proliferative disorders
08/25/2005US20050186205 Administering unlabelled anti-CD20 antibody that binds to the CD20 antigen present on lymphoma cells; a second treatment of cyclophosphamide, doxorubicin, vincristine or prednisone
08/25/2005US20050186202 Mouse-human chimeric variants of CC49 with minimal murine content in which less than all six (three heavy chain and three light chain) Complementarity Determining Regions are present
08/25/2005US20050186136 Soluble JAM-1, 2, and 3 as diagnostic & prognostic markers in cardiovascular, vascular, and inflammatory disorders
08/25/2005US20050186135 therapy for tumors, lesions, cancer by in situ supplying peroxide and hypochlorite; drug delivery
08/25/2005US20050186134 Method for preparing technetium-labeled antimony sulfide nanocolloid
08/25/2005CA2819492A1 Therapeutic and diagnostic conjugates for use with multispecific antibodies
08/25/2005CA2555666A1 Therapeutic and diagnostic conjugates for use with multispecific antibodies
08/25/2005CA2555597A1 Radiolabeled compounds and compositions, their precursors and methods for their production
08/24/2005EP1204426B1 Medical preparation for treating arthrosis, arthritis and other rheumatic joint diseases
08/24/2005CN1658907A Radiopharmaceutical formulations
08/23/2005US6933114 Nucleotide sequence ligand for use in the detection diagnosis and treatment of cancer
1 ... 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 ... 243